Related Experiment Videos
Antiangiogenesis by cyclosporine
M Iurlaro1, A Vacca, M Minischetti
1Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy.
Experimental Hematology
|December 9, 1998
Summary
Low-dose cyclosporine inhibits endothelial cell functions and angiogenesis without cytotoxicity. This drug
Area of Science:
- Endocrinology
- Cell Biology
- Pharmacology
Background:
- Endothelial cell functions are crucial for angiogenesis.
- Cyclosporine is an immunosuppressant drug.
- Understanding cyclosporine's effects on endothelial cells is important for its therapeutic applications.
Purpose of the Study:
- To investigate the effects of cyclosporine on endothelial cell functions in vitro.
- To evaluate the impact of cyclosporine on angiogenesis in vivo.
- To explore the underlying biochemical mechanisms of cyclosporine's action.
Main Methods:
- In vitro studies assessed endothelial cell proliferation, chemotaxis, morphogenesis, and matrix metalloprotease (MMP)-2 and MMP-9 secretion.
- In vivo angiogenesis was studied using the chick embryo chorioallantoic membrane (CAM) model.
- Biochemical assays measured the activity of endothelial cell respiratory chain enzymes.
Main Results:
- Low, noncytotoxic doses of cyclosporine inhibited endothelial cell functions and angiogenesis in a dose-dependent manner.
- Cyclosporine demonstrated antiangiogenic activity in the CAM model.
- The drug inhibited endothelial cell respiratory chain enzymes, suggesting a potential mechanism of action.
Conclusions:
- Low-dose cyclosporine exhibits antiangiogenic properties.
- These findings suggest potential therapeutic applications for cyclosporine in diseases with enhanced angiogenesis.
- Further research is warranted to explore cyclosporine's role in autoimmune and neoplastic diseases.